MCID: ADR040
MIFTS: 37

Adrenal Gland Pheochromocytoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Pheochromocytoma

MalaCards integrated aliases for Adrenal Gland Pheochromocytoma:

Name: Adrenal Gland Pheochromocytoma 12 15
Pheochromocytoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050892
UMLS 73 C0031511

Summaries for Adrenal Gland Pheochromocytoma

Disease Ontology : 12 An adrenal medulla cancer that is characterized by overproduction of adrenaline.

MalaCards based summary : Adrenal Gland Pheochromocytoma, also known as pheochromocytoma, is related to pheochromocytoma and adrenal carcinoma, and has symptoms including tremor, fever and abdominal pain. An important gene associated with Adrenal Gland Pheochromocytoma is NOS3 (Nitric Oxide Synthase 3), and among its related pathways/superpathways are Prolactin Signaling Pathway and Apoptosis Pathway. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, testes and heart, and related phenotypes are cardiovascular system and muscle

Related Diseases for Adrenal Gland Pheochromocytoma

Diseases related to Adrenal Gland Pheochromocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 pheochromocytoma 11.7
2 adrenal carcinoma 11.3
3 autosomal dominant polycystic kidney disease 9.8 MTOR NOS3
4 body mass index quantitative trait locus 11 9.5 KCNH2 MTOR NOS3

Symptoms & Phenotypes for Adrenal Gland Pheochromocytoma

UMLS symptoms related to Adrenal Gland Pheochromocytoma:


tremor, fever, abdominal pain, chest pain, headache

MGI Mouse Phenotypes related to Adrenal Gland Pheochromocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.26 BNIP3 KCNH2 MTOR NOS3
2 muscle MP:0005369 8.92 BNIP3 KCNH2 MTOR NOS3

Drugs & Therapeutics for Adrenal Gland Pheochromocytoma

Drugs for Adrenal Gland Pheochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 4,Phase 3,Phase 2 59-96-1 4768
3 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Vasodilator Agents Phase 4,Phase 3,Phase 2
6 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
7 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
8 Antihypertensive Agents Phase 4,Phase 3,Phase 2
9 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
10
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 51110-01-1, 38916-34-6 53481605
11
Lenograstim Approved, Investigational Phase 3 135968-09-1
12
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
13
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
14
Ifosfamide Approved Phase 3 3778-73-2 3690
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 Radiopharmaceuticals Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Hormones Phase 2, Phase 3,Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
20 Hormone Antagonists Phase 2, Phase 3,Phase 1
21
Isophosphamide mustard Phase 3 0
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 3,Phase 2
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
26 Alkylating Agents Phase 3,Phase 2,Phase 1
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Indinavir Approved Phase 2 150378-17-9 5362440
29
Racepinephrine Approved Phase 2,Not Applicable 329-65-7 838
30
Epinephrine Approved, Vet_approved Phase 2,Not Applicable 51-43-4 5816
31
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
32
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
33
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
34
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
35
Carbidopa Approved Phase 2 28860-95-9 34359 38101
36
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 7553-56-2 807
37
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
38
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
39
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
40
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
41
Tamoxifen Approved Phase 2 10540-29-1 2733526
42
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
43
Pancrelipase Approved, Investigational Phase 2,Not Applicable 53608-75-6
44
Melphalan Approved Phase 2 148-82-3 4053 460612
45
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
46
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
47
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
48
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
49
Lenvatinib Approved, Investigational Phase 2 417716-92-8
50
Azacitidine Approved, Investigational Phase 2 320-67-2 9444

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
2 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
8 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
9 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
12 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
13 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NCT00843037 Phase 2 Sunitinib
14 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
15 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001
16 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
20 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
21 Phase II Study of Vandetanib in Individuals With Kidney Cancer Completed NCT00566995 Phase 2 ZACTIMA (Vandetanib) (ZD6474)
22 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Completed NCT00088374 Phase 2 17 allylamino-17-demethoxygeldanamycin;18 FDG (Fludeoxyglucose 18F);[15-O] H2O;EPL diluent
23 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2 Lenvatinib
24 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
25 Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib
26 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;Amino Acid solution
27 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Recruiting NCT00107289 Phase 2
28 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
29 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
30 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
31 MIBG Therapy for Patients With MIBG Avid Tumors Recruiting NCT02378428 Phase 2 MIBG
32 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
33 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
34 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
35 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2 Dovitinib
36 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
37 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
38 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
39 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
40 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
41 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
42 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
43 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
44 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
45 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
46 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
47 Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Unknown status NCT02186678 Not Applicable
48 Evaluation of Plasma Catecholamine Concentration During Surgery Unknown status NCT00948181
49 Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card Unknown status NCT02672020 Not Applicable
50 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335

Search NIH Clinical Center for Adrenal Gland Pheochromocytoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Adrenal Gland Pheochromocytoma

Anatomical Context for Adrenal Gland Pheochromocytoma

MalaCards organs/tissues related to Adrenal Gland Pheochromocytoma:

41
Adrenal Gland, Testes, Heart, Kidney, Liver, Bone, Thyroid

Publications for Adrenal Gland Pheochromocytoma

Articles related to Adrenal Gland Pheochromocytoma:

(show top 50) (show all 621)
# Title Authors Year
1
Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B. ( 30113649 )
2019
2
Oncometabolite induced primary cilia loss in pheochromocytoma. ( 30345732 )
2019
3
Radiomics improves efficiency for differentiating subclinical pheochromocytoma from lipid-poor adenoma: a predictive, preventive and personalized medical approach in adrenal incidentalomas. ( 30538793 )
2018
4
Pheochromocytoma - An incidental finding in a child with acute appendicitis. ( 30504959 )
2018
5
Adrenergic cardiomyopathy and cardiogenic shock as initial presentation of pheochromocytoma. A case report and review of the literature. ( 30007262 )
2018
6
Extracorporeal membrane oxygenation in pheochromocytoma-induced cardiogenic shock. ( 28823181 )
2018
7
A Rare Case Report of Extra-adrenal Pheochromocytoma with Normal Blood Pressure: Is that Possible? ( 30357026 )
2018
8
Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma. ( 30542047 )
2018
9
Multifocal pheochromocytoma-paraganglioma in a 29-year-old woman with cyanotic congenital heart disease. ( 30340856 )
2018
10
Pheochromocytoma in Congenital Cyanotic Heart Disease. ( 30356369 )
2018
11
Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1. ( 29623209 )
2018
12
Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. ( 30467902 )
2018
13
Hypoxia Signaling and Circadian Disruption in and by Pheochromocytoma. ( 30386298 )
2018
14
Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. ( 30109021 )
2018
15
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. ( 29099418 )
2018
16
Propofol Prevents the Progression of Malignant Pheochromocytoma In Vitro and In Vivo. ( 29565198 )
2018
17
131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study. ( 29645065 )
2018
18
Giant malignant pheochromocytoma in an elderly patient: A case report. ( 29742697 )
2018
19
What determines mortality in malignant pheochromocytoma? - Report of a case with eighteen-year survival and review of the literature. ( 29768630 )
2018
20
Successful treatment of malignant pheochromocytoma with sacrum metastases: A case report. ( 30170467 )
2018
21
Malignant Pheochromocytoma with Widespread Bony and Pulmonary Metastases. ( 30483454 )
2018
22
First report of concomitant pheochromocytoma and duodenal neuroendocrine tumour in a sporadic multiple endocrine neoplasia type 1. ( 30181398 )
2018
23
An Autopsy Case of Sudden Death in Neurofibromatosis Type 1 With Pheochromocytoma and Myocarditis. ( 29210711 )
2018
24
Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease. ( 30182289 )
2018
25
Two Childhood Pheochromocytoma Cases due to von Hippel-Lindau Disease, One Associated with Pancreatic Neuroendocrine Tumor: A Very Rare Manifestation ( 29022557 )
2018
26
New insights on the pathogenesis of paraganglioma and pheochromocytoma. ( 30345003 )
2018
27
Germline SDHB and SDHD mutations in pheochromocytoma and paraganglioma patients. ( 30352407 )
2018
28
Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. ( 30352425 )
2018
29
Retroperitoneal paraganglioma: a chameleon masquerading as an adrenal pheochromocytoma. ( 30371110 )
2018
30
Simultaneous Pheochromocytoma, Paraganglioma, and Papillary Thyroid Carcinoma without Known Mutation. ( 30405919 )
2018
31
Regarding: A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. ( 30409407 )
2018
32
Metabolic subtyping of pheochromocytoma and paraganglioma by 18F-FDG pharmacokinetics using dynamic PET/CT scanning. ( 30413658 )
2018
33
Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior. ( 30451732 )
2018
34
Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. ( 30536464 )
2018
35
Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma. ( 29305799 )
2018
36
Trends of genetic screening in patients with pheochromocytoma and paraganglioma: 15-year experience in a high-volume tertiary referral center. ( 29315604 )
2018
37
Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan. ( 29353821 )
2018
38
Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. ( 29361475 )
2018
39
Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma. ( 29464059 )
2018
40
CORRIGENDUM FOR "Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study". ( 29538659 )
2018
41
Multifocal Paraganglioma and Pheochromocytoma Due to Truncated SDHD Mutation. ( 29545045 )
2018
42
External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. ( 29556576 )
2018
43
Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. ( 29623478 )
2018
44
Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. ( 29636359 )
2018
45
Paraganglioma or pheochromocytoma? A peculiar diagnosis. ( 29644041 )
2018
46
Hereditary paraganglioma-pheochromocytoma syndrome. ( 29656766 )
2018
47
Co-Occurrence of Pheochromocytoma-Paraganglioma and Cyanotic Congenital Heart Disease: A Case Report and Literature Review. ( 29719528 )
2018
48
Re-operative Surgery for Pheochromocytoma-Paraganglioma: Analysis of 13 Cases from a Single Institution. ( 29915477 )
2018
49
Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. ( 30008476 )
2018
50
Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Meta-Analysis. ( 30030341 )
2018

Variations for Adrenal Gland Pheochromocytoma

Cosmic variations for Adrenal Gland Pheochromocytoma:

9 (show top 50) (show all 62)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.593T>C p.L198P 3:10149916-10149916 7
2 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.389T>G p.V130G 3:10146562-10146562 7
3 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.491A>G p.Q164R 3:10149814-10149814 7
4 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.492G>T p.Q164H 3:10149815-10149815 7
5 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.482G>A p.R161Q 3:10149805-10149805 7
6 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.499C>T p.R167W 3:10149822-10149822 7
7 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 7
8 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 7
9 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 7
10 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.475A>G p.K159E 3:10149798-10149798 7
11 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.496G>T p.V166F 3:10149819-10149819 7
12 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 7
13 COSM44914 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 7
14 COSM43678 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 7
15 COSM10662 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 7
16 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.1900T>C p.C634R 10:43114500-43114500 7
17 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.2753T>C p.M918T 10:43121968-43121968 7
18 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1885G>A p.Q616fs*4 17:31225134-31225134 7
19 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1721+3A>T p.A548fs*13 17:31221932-31221932 7
20 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7646C>G p.S2549* 17:31356490-31356490 7
21 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.226G>T p.E76* 17:31159031-31159031 7
22 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.5665G>T p.E1889* 17:31330351-31330351 7
23 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1722-1G>A p.? 17:31223443-31223443 7
24 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1466A>G p.Y489C 17:31214524-31214524 7
25 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3158C>A p.S1053* 17:31230886-31230886 7
26 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7582C>T p.Q2528* 17:31352381-31352381 7
27 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.6855C>A p.Y2285* 17:31338739-31338739 7
28 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.4558C>T p.Q1520* 17:31260496-31260496 7
29 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7300C>T p.Q2434* 17:31349230-31349230 7
30 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3721C>T p.R1241* 17:31235623-31235623 7
31 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.2409+1G>A p.A776_Q803del 17:31227607-31227607 7
32 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.205-1G>C p.R69fs*7 17:31159009-31159009 7
33 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.352A>T p.M118L 7:116699436-116699436 7
34 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.3029C>T p.T1010I 7:116771936-116771936 7
35 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.607T>A p.S203T 7:116699691-116699691 7
36 COSM6342201 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.6797T>C p.F2266S 12:49040163-49040163 7
37 COSM5945783 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14858A>G p.N4953S 12:49026298-49026298 7
38 COSM144597 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7019T>C p.L2340P 12:49039941-49039941 7
39 COSM5945788 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7954C>T p.R2652W 12:49038592-49038592 7
40 COSM5945782 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7393G>A p.G2465S 12:49039461-49039461 7
41 COSM5945789 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14856C>A p.N4952K 12:49026300-49026300 7
42 COSM5945787 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.11854C>G p.L3952V 12:49032041-49032041 7
43 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.181C>A p.Q61K 11:533875-533875 7
44 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.182A>G p.Q61R 11:533874-533874 7
45 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.37G>C p.G13R 11:534286-534286 7
46 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,NS c.103G>T p.G35W 1:226064454-226064454 7
47 COSM27887 GNAS adrenal gland,adrenal gland,pheochromocytoma,NS c.601C>T p.R201C 20:58909365-58909365 7
48 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1638C>A p.N546K 8:38417331-38417331 7
49 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1592C>T p.P531L 2:46380264-46380264 7
50 COSM6188659 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1591C>T p.P531S 2:46380263-46380263 7

Expression for Adrenal Gland Pheochromocytoma

Search GEO for disease gene expression data for Adrenal Gland Pheochromocytoma.

Pathways for Adrenal Gland Pheochromocytoma

GO Terms for Adrenal Gland Pheochromocytoma

Cellular components related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 8.62 BNIP3 MTOR

Biological processes related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 8.96 BNIP3 MTOR
2 cardiac muscle contraction GO:0060048 8.62 KCNH2 MTOR

Molecular functions related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.13 BNIP3 KCNH2 MTOR
2 scaffold protein binding GO:0097110 8.62 KCNH2 NOS3

Sources for Adrenal Gland Pheochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....